This Global website is not intended to represent or suggest that particular products are approved or authorized in any particular jurisdiction. You should not construe anything on this website as a promotion or solicitation for any product or service, or as suggesting that a product or service be used where it is not approved or authorized by applicable law and regulation in a particular country, territory, or jurisdiction. To learn which products are approved or authorized in particular countries, please consult the appropriate
Bleeding disorders, also called coagulopathies, occur when coagulation (blood clotting) is defective. Excessive and prolonged bleeding can occur if a particular component of coagulation is deficient or dysfunctional. Such bleeding can vary in severity and duration and can cause symptoms that range from nosebleeds, bleeding gums, bruising, heavy menstruation, blood in the stool or urine to bleeding into joints causing arthritic-type symptoms, loss of vision and chronic anemia.1
Bleeding disorders are broadly classified as congenital (inherited) or acquired:
- Congenital bleeding disorders are caused by defects or damage in a developing fetus. Congenital defects can be due to inherited abnormalities in genes or chromosomes or to intrauterine conditions, such as infections.2
- Acquired bleeding disorders are those that develop or spontaneously occur in the individual.3
Starting a century ago, CSL Behring made a promise to save lives and protect the health of people who were stricken with a range of serious and chronic medical conditions. This promise began in 1901, when
Emil von Behring won the first Nobel Prize in Physiology and Medicine for his work on serum therapies.
In 1954, we produced the world's first pasteurized plasma protein solution. In doing so, CSL Behring became the first company in the world to fractionate plasma proteins from human plasma in quantities large enough to make them widely available for the treatment of bleeding disorders. In 1981, we marketed the world's first pasteurized factor VIII therapy to treat patients with hemophilia A.
Today, we focus our world-class research and development, high-quality manufacturing, and patient-centered management to develop and deliver innovative biotherapies and support programs for people with a wide range of bleeding disorders such as
Von Willebrand Disease ,
hemophilia A and
fibrinogen deficiency, and other rare and serious factor deficiencies. Emerging new innovations from our recombinant factor development program will soon provide unprecedented opportunities to potentially improve hemophilia A and B patient well-being.
CSL Behring's substantial investments in state-of-the-art facilities for production of our recombinant proteins in Broadmeadows (Australia), Parkville (Australia), Marburg (Germany) and Lengnau (Switzerland) further demonstrate our drive to care for patients and deliver on our commitments to the global bleeding disorders community.
1. Ma A. Evaluation of the bleeding patient. In: Key N, Makris M, O'Shaughnessy D, Lillicrap D, editors. Practical Hemostasis and Thrombosis. 2nd ed: Wiley-Blackwell, 2009:48–60.
2. Asselta R, Duga S, Tenchini ML. The molecular basis of quantitative fibrinogen disorders. J Thromb Haemost 2006;4(10):2115-29.
3. Peyvandi F, Palla R. Fibrinogen concentrates. Clin Adv Hematol Oncol 2009;7(12):788-90.